Logo

APLM

Apollomics, Inc.

APLM

Apollomics, Inc. • NASDAQ
$15.05 ▼ -1.25% (-0.19)
Market Cap $16.61 M
52w High $42.12
52w Low $3.66
Dividend Yield 0%
P/E -0.29
Volume 104.32K
Outstanding Shares 1.10M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $-1.57M ▼ $15.255M ▼ $-18.652M ▲ 1.188K% ▲ $-16.92 ▲ $-15.779M ▲
Q2-2024 $1.768M ▲ $27.079M ▼ $-35.206M ▼ -1.991K% ▲ $-37.56 ▼ $-25.276M ▲
Q4-2023 $333K ▼ $28.664M ▲ $-21.907M ▲ -6.579K% ▲ $-0.24 ▲ $-27.824M ▼
Q2-2023 $488K ▲ $26.17M ▲ $-150.694M ▲ -30.88K% ▼ $-2.56 ▼ $-25.622M ▼
Q4-2022 $-272K $22.308M $-237.394M 87.277K% $-0.001 $-21.461M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $9.766M ▼ $13.098M ▼ $8.234M ▼ $4.864M ▼
Q2-2024 $25.929M ▼ $34.573M ▼ $13.766M ▼ $20.807M ▼
Q4-2023 $37.817M ▼ $55.387M ▼ $14.153M ▼ $41.234M ▼
Q2-2023 $52.616M ▼ $71.378M ▼ $15.681M ▼ $55.697M ▲
Q4-2022 $54.614M $76.475M $524.595M $-448.12M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-18.652M ▲ $-12.755M ▲ $236K ▼ $-3.652M ▼ $0 $-12.755M ▲
Q2-2024 $-35.206M ▼ $-15.988M ▲ $5.747M ▼ $4.12M ▲ $0 $-16.012M ▲
Q4-2023 $-21.907M ▲ $-18.812M ▲ $21.607M ▲ $3.984M ▼ $0 $-18.812M ▲
Q2-2023 $-150.694M ▲ $-24.397M ▼ $-242K ▼ $17.241M ▲ $0 ▲ $-24.403M ▼
Q4-2022 $-237.394M $-23.098M $5.214M $-141K $-50.7M $-23.128M

Five-Year Company Overview

Income Statement

Income Statement Apollomics is still a pure R&D biotech story with no product revenue, so all activity flows through as research and operating costs. Losses have been consistent over the past several years and remain meaningful relative to the company’s very small size. Net loss has been volatile, reflecting shifts in financing costs, one‑offs, and changing R&D intensity. Overall, the income statement shows a business fully in the investment phase, with profitability entirely dependent on future drug approvals, not current operations.

Balance Sheet

Balance Sheet The balance sheet is light, with a modest asset base largely made up of cash and very little in the way of physical assets. The company carries no traditional financial debt, which simplifies the capital structure but does not remove funding risk, because it still depends on new capital to support trials. Shareholders’ equity has been thin and at times negative, signaling accumulated losses and a fragile capital position. This, combined with the recent reverse split history, underscores that balance‑sheet strength is limited and sensitive to future fund‑raising and trial outcomes.

Cash Flow

Cash Flow Cash flows are negative and dominated by operating outflows tied to clinical development and overhead, which is typical for a clinical‑stage biotech. Free cash flow closely tracks operating cash flow because capital spending needs are minimal. The pattern shows a steady cash burn rather than sharp spikes, but even a steady burn is significant given the small cash base. The stated runway into 2025 highlights a finite time window to secure additional funding, partnerships, or cost reductions before liquidity again becomes a pressing issue.

Competitive Edge

Competitive Edge Apollomics competes in a very crowded and fast‑moving oncology space, where many larger and better‑funded players are also targeting similar pathways. Its main competitive asset is vebreltinib, which has a differentiated profile as a selective, brain‑penetrant c‑Met inhibitor aimed at genetically defined patient groups. Partnerships in China and parts of Asia provide regional leverage and potential non‑US revenue pathways if the drug succeeds. However, the discontinuation of uproleselan and the heavy reliance on a single lead asset increase concentration risk versus more diversified oncology peers.

Innovation and R&D

Innovation and R&D The company’s strategy centers on precision oncology and immuno‑oncology, combining targeted therapies with immune‑based approaches. Vebreltinib is the flagship, with features designed to address unmet needs in certain lung cancers and other tumors driven by MET alterations, including potential brain involvement. Beyond that, Apollomics maintains a multi‑asset pipeline, but recent cost cuts and reprioritization clearly funnel resources toward the most advanced and promising programs. The ability to generate and in‑license novel candidates, backed by an expanding patent portfolio, supports innovation, but success still hinges on converting this science into convincing clinical data.

Summary

Apollomics is an early‑stage, high‑risk biotech with no commercial products, ongoing losses, and a limited but debt‑free balance sheet, typical of companies in its development stage. The investment story is now tightly anchored to the clinical and regulatory path of vebreltinib after the setback with uproleselan. Partnerships and intellectual property provide some competitive support, but do not remove the core uncertainties around trial success, regulatory approval, and future financing. Overall, the company’s prospects depend heavily on scientific execution and capital access over the next few years, rather than on current financial performance.

NEWS

November 19, 2025 · 5:38 PM UTC

Apollomics Announces Settlement of Cayman Litigation

Read more

November 17, 2025 · 11:00 PM UTC

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Read more

October 15, 2025 · 2:36 PM UTC

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Read more

October 14, 2025 · 4:05 PM UTC

Nasdaq Resumes Trading in Apollomics Inc.

Read more

October 13, 2025 · 9:22 PM UTC

Apollomics, Inc. Company Operational Continuity Update

Read more